Featured Research
The Crohn's & Colitis Foundation collaborates with academic and industry researchers to help enroll patients with Crohn’s disease and ulcerative colitis into clinical studies. The list below highlights our partners' current research studies. Please note that these partners have paid to have their trials posted below, and the Crohn's & Colitis Foundation does not endorse any particular study.
For a comprehensive listing of all research studies currently recruiting, please visit our IBD Clinical Trial Finder.
Current Results: 20 entries
To assess the safety of, as well as how a natural product derived from the Hops plant is broken down by the bacteria in the intestines of adults with Crohn’s disease.
To Evaluate the Safety and Efficacy of PN-943 Treatment in Patients with Moderate to Severe Active Ulcerative Colitis.
To assess the safety and tolerability and early proof of efficacy of TAK-018 in patients with Crohn’s Disease who are planning to undergo surgery to remove the diseased ileo-cecal region of the bowel.
The primary objective is to evaluate the safety, tolerability and efficacy of two doses of etrasimod as induction therapy in participants with moderately to severely active Crohn’s disease.
The purpose of the study is to evaluate the safety and effectiveness of the study medicine in adults with ulcerative colitis.
Primary objective: To compare clinical efficacy by evaluating the clinical response to CBP-307 (P.O. for 12 consecutive weeks) versus placebo in subjects with moderate to severe UC
Primary Objective: To Evaluate the Effect of GB004 Compared to Placebo on Clinical Remission
The purpose of the LATTICE-CD is to evaluate how well an oral investigational drug (called BMS- 986165) works and how safe it is for patients with moderately to severely active Crohn’s disease.
To assess the change in symptoms and overall safety of TD-1473, which is an investigational product, in moderately-to-severely active Crohn's disease.
- To evaluate the efficacy of PF-06480605 in induction of clinical remission at Week 14 in participants with moderate to severe active UC.
- To evaluate the safety and tolerability of PF-06480605 during the chronic therapy period (from Week 14 to the End of Study Visit) in participants with moderate to severe active UC during the chronic therapy period.